Knowledge base
1,270 claims across 14 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,270ai alignment 325internet finance 263health 207space development 171entertainment 131grand strategy 101energy 23mechanisms 18collective intelligence 14manufacturing 5robotics 5critical systems 3unknown 3teleological economics 1
US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 accordin
The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Au
Value-based care requires enrollment stability as structural precondition because prevention ROI depends on multi-year attribution and semi-annual redeterminations break the investment timeline
The OBBBA introduces semi-annual eligibility redeterminations (starting October 1, 2026) that structurally undermine VBC economics. VBC prevention investments — CHW programs, chronic disease management, SDOH interventions — require 2-4 year attribution windows to capture ROI because health improveme
GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
The central economic objection to value-based care transition has been that prevention doesn't pay within typical contract horizons. Providers accept upside bonuses but avoid downside risk because the financial case for investing in health (rather than treating sickness) requires a longer payback pe
after a threshold of material development relative deprivation replaces absolute deprivation as the primary driver of health outcomes
Wilkinson's epidemiological transition framework identifies a structural shift in what determines population health. Below a GDP-per-capita threshold, absolute wealth is the dominant predictor — richer societies are healthier because they can afford nutrition, sanitation, healthcare, and shelter. Ab
Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
Empirical testing reveals clinical AI hallucination rates span a 100x range depending on task complexity: ambient scribes (structured transcription) achieve 1.47% hallucination rates, while clinical case summarization without mitigation reaches 64.1%. GPT-4o with structured mitigation drops from 53%
GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
The Lancet frames the GLP-1 equity problem as structural policy failure, not market failure. Populations most likely to benefit from GLP-1 drugs—those with high cardiometabolic risk, high obesity prevalence (lower income, Black Americans, rural populations)—face the highest access barriers through M
GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide
Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of de
No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
Despite clinical AI hallucination rates ranging from 1.47% to 64.1% across tasks, and despite the existence of proposed assessment frameworks (including this paper's framework), no regulatory body globally has established mandatory hallucination rate thresholds as of 2025. FDA enforcement discretion
State clinical AI disclosure laws fill a federal regulatory gap created by FDA enforcement discretion expansion because California Colorado and Utah enacted patient notification requirements while FDA's January 2026 CDS guidance expanded enforcement discretion without adding disclosure mandates
California enacted two sequential clinical AI laws: AB 3030 (effective January 1, 2025) requires health facilities to notify patients when using generative AI to communicate clinical information and provide instructions for human contact; AB 489 (effective January 1, 2026) prohibits AI from misrepre
US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structu
Ambient AI scribes create simultaneous malpractice exposure for clinicians, institutional liability for hospitals, and product liability for manufacturers while operating outside FDA medical device regulation
Ambient AI scribes create a novel three-party liability structure that existing malpractice frameworks are not designed to handle. Clinician liability: physicians who sign AI-generated notes containing errors (fabricated diagnoses, wrong medications, hallucinated procedures) bear malpractice exposur
Ambient AI scribes are generating wiretapping and biometric privacy lawsuits because health systems deployed without patient consent protocols for third-party audio processing
Ambient AI scribes are facing an unanticipated legal attack vector through wiretapping and biometric privacy statutes. Lawsuits filed in California and Illinois (2025-2026) allege health systems used ambient scribing without patient informed consent, potentially violating: California's Confidentiali
Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years
ECRI, the most credible independent patient safety organization in the US, ranked misuse of AI chatbots as the #1 health technology hazard in both 2025 and 2026. This is not theoretical concern but documented harm tracking. Specific documented failures include: incorrect diagnoses, unnecessary testi
The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
The clinical AI safety vacuum operates at both ends of the deployment lifecycle. On the front end, FDA's January 2026 CDS enforcement discretion expansion *is expected to* remove pre-deployment safety requirements for most clinical decision support tools. On the back end, this paper documents that M
FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance
FDA's revised CDS guidance introduces enforcement discretion for CDS tools that provide a single output where 'only one recommendation is clinically appropriate' — explicitly including AI and generative AI. Covington notes this 'covers the vast majority of AI-enabled clinical decision support tools
FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
Of 429 FDA MAUDE reports associated with AI/ML-enabled medical devices, 148 reports (34.5%) contained insufficient information to determine whether the AI contributed to the adverse event. This is not a data quality problem but a structural design gap: MAUDE lacks the fields, taxonomy, and reporting
FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
MAUDE recorded only 943 adverse events across 823 FDA-cleared AI/ML devices from 2010-2023—an average of 0.76 events per device over 13 years. For comparison, FDA reviewed over 1.7 million MDRs for all devices in 2023 alone. This implausibly low rate is not evidence of AI safety but evidence of surv
FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable
FDA explicitly acknowledged concern about 'how HCPs interpret CDS outputs' in the 2026 guidance, formally recognizing automation bias as a real phenomenon. However, the agency's proposed solution reveals a fundamental misunderstanding of the mechanism: FDA requires transparency about data inputs and
Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects
Generative AI medical devices violate the core assumptions of existing regulatory frameworks in three ways: (1) Non-determinism — the same prompt yields different outputs across sessions, breaking the 'fixed algorithm' assumption underlying FDA 510(k) clearance and EU device testing; (2) Continuous
Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
The FDA's January 6, 2026 CDS enforcement discretion expansion and ECRI's January 2026 publication of AI chatbots as the #1 health technology hazard occurred in the same 30-day window. This temporal coincidence represents the clearest evidence that deregulation is occurring during active harm accumu
food as medicine interventions produce clinically significant improvements during active delivery but benefits fully revert when structural food environment support is removed
A randomized controlled trial presented at AHA 2025 examined DASH-style grocery delivery plus dietitian support versus cash stipends in food-insecure Black adults in Boston. During the 12-week active intervention, the groceries + dietitian arm showed statistically significant BP improvement and LDL
food insecurity independently predicts 41 percent higher cvd incidence establishing temporality for sdoh cardiovascular pathway
The CARDIA prospective cohort study followed 3,616 US adults without preexisting CVD from 2000 to 2020 (mean baseline age 40.1 years, 56% female, 47% Black). Food insecurity at baseline was associated with HR 1.41 for incident CVD after adjustment for income, education, and employment. This is the f
Medically tailored meals produce -9.67 mmHg systolic BP reductions in food-insecure hypertensive patients — comparable to first-line pharmacotherapy — suggesting dietary intervention at the level of structural food access is a clinical-grade treatment for hypertension
The Kentucky MTM pilot enrolled 75 food-insecure hypertensive adults across urban (UK HealthCare) and rural (Appalachian Regional Healthcare) sites. The medically tailored meals arm (5 meals/week for 12 weeks) produced -9.67 mmHg systolic BP reduction, while the grocery prescription arm ($100/month
Page 5 of 9